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ABSTRACT
Objective To evaluate whether including a test for faecal
calprotectin, a sensitive marker of intestinal
inflammation, in the investigation of suspected
inflammatory bowel disease reduces the number of
unnecessary endoscopic procedures.
Design Meta-analysis of diagnostic accuracy studies.
Data sources Studies published in Medline and Embase
up to October 2009.
Interventions reviewed Measurement of faecal
calprotectin level (index test) compared with endoscopy
and histopathology of segmental biopsy samples
(reference standard).
Inclusion criteria Studies that had collected data
prospectively in patients with suspected inflammatory
bowel disease and allowed for construction of a two by
two table. For each study, sensitivity and specificity of
faecal calprotectin were analysed as bivariate data to
accountforapossiblenegativecorrelationwithinstudies.
Results 13 studies were included: six in adults (n=670),
seven in children and teenagers (n=371). Inflammatory
bowel disease was confirmed by endoscopy in 32%
(n=215) of the adults and 61% (n=226) of the children
and teenagers. In the studies of adults, the pooled
sensitivityandpooledspecificityofcalprotectinwas0.93
(95% confidence interval 0.85 to 0.97) and 0.96 (0.79 to
0.99) and in the studies of children and teenagers was
0.92 (0.84 to 0.96) and 0.76 (0.62 to 0.86). The lower
specificity in the studies of children and teenagers was
significantly different from that in the studies of adults
(P=0.048). Screening by measuring faecal calprotectin
levels would result in a 67% reduction in the number of
adults requiring endoscopy. Three of 33 adults who
undergo endoscopy will not have inflammatory bowel
disease but may have a different condition for which
endoscopy is inevitable. The downside of this screening
strategyisdelayeddiagnosisin6%ofadultsbecauseofa
false negative test result. In the population of children
and teenagers, 65 instead of 100 would undergo
endoscopy. Nine of them will not have inflammatory
boweldisease,anddiagnosiswillbedelayedin8%ofthe
affected children.
Conclusion Testing for faecal calprotectin is a useful
screening tool for identifying patients who are most likely
to need endoscopy for suspected inflammatory bowel
disease. The discriminative power to safely exclude
inflammatory bowel disease was significantly better in
studies of adults than in studies of children.
INTRODUCTION
The incidence of inflammatorybowel disease is on the
increase in both adults and children.
12 The disorder
includes two major forms of chronic intestinal inflam-
mation: Crohn’s disease and ulcerative colitis. Suspi-
cion is raised in patients with persistent (≥4 weeks) or
recurrent (≥2 episodes in six months) abdominal pain
and diarrhoea. Additionally, rectal bleeding, weight
loss, or anaemia increase the probability of the
condition.
34 Pathognomonic signs or symptoms do
not exist. Endoscopic evaluation with histopathologi-
calsamplingaregenerallyconsideredindispensablein
the investigation of patients with suspected inflamma-
tory bowel disease.
34 Many patients consider endo-
scopy and the required bowel preparation to be
uncomfortable.
5Inarelativelylargeproportionofpeo-
ple with suspected inflammatory bowel disease the
resultsofendoscopywillbenegative.
6Athirdofadults
withbleedingrelatedsymptomshavenoabnormalities
on endoscopy, and this proportion increases to half
with non-bleeding symptoms such as diarrhoea,
abdominal pain, and weight loss. Identification of low
risk patients would reduce the number of unnecessary
invasive endoscopic procedures. Conversely, doctors
wouldliketobeabletoidentifythosewithasufficiently
high likelihood of inflammatory bowel disease to jus-
tify urgency for endoscopy.
Use of a simple, non-invasive, and cheap screening
test to make a presumptive diagnosis of inflammatory
bowel disease would help to reach these goals. Deter-
mination of calprotectin levels in stools could be a
good screening method. Calprotectin is a major pro-
tein found in the cytosol of inflammatory cells.
7 The
protein is stable in stool samples for up to seven days
at room temperature and one sample of less than 5 g is
sufficient for a reliable measurement.
8 These qualities
allowforstoolsamplecollectionathomeandpotential
delays in transport to the laboratory.
Since2000,faecalcalprotectinhasbeenevaluatedin
numerous diagnostic studies in both adult and paedia-
tric populations. Many of these studies included
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patients with known inflammatory bowel disease on
the other. Both extremes give cause to overestimation
of diagnostic accuracy relative to the practical situa-
tion,wherescreeningisnecessarybecauseit isdifficult
to clinically distinguish between those who do and
those who do not need urgent endoscopy. The doctor
is then left with little guidance about the usefulness of
faecal calprotectin as a screening test.We carriedout a
meta-analysis to evaluate whether adding faecal cal-
protectin testing to the investigation of patients with
suspected inflammatory bowel disease reduced the
number of unnecessary endoscopies.
METHODS
Eligible studies were those that assessed the diagnostic
accuracy of faecal calprotectin testing in patients with
inflammatory bowel disease suspected on clinical
grounds. Data collection had to be done prospectively
withstoolsampling(indextest)beforeendoscopiceva-
luation including histopathological verification of seg-
mental biopsies (reference standard).
Identification of studies
We searched for diagnostic studies published in Med-
lineandEmbaseuptoOctober2009.Thesearchstrat-
egy for Medline was (“Leukocyte L1 Antigen
Complex”[Mesh] OR “calprotectin”[tw]) AND
(“Inflammatory Bowel Diseases”[Mesh] OR “inflam-
matory bowel disease”[tw] OR “inflammatory bowel
diseases”[tw] OR “IBD”[tw] OR “Crohn”[tw] OR
“Colitis”[tw]). For Embase we used (“calgranulin”/
exp OR “calprotectin”/exp) AND (“enteritis”/exp
OR “inflammatory bowel disease”/exp OR “inflam-
matory bowel diseases”/exp OR “ibd” OR “crohn”
OR “colitis”/exp) AND [embase]/lim.
WerestrictedoursearchtostudiespublishedinEng-
lish only. Duplicate articles identified in both Medline
and Embase were manually deleted using Reference
Manager,version11(ThomsonReuters,Philadelphia,
PA). For further relevant studies we checked the refer-
ence lists of identified trials.
Study selection and data extraction
The first selection was carried out by one reviewer
(PFvR), on the basis of the title and abstract. The full
paper of each potentially eligible study was then
obtained. Two reviewers (PFvR, EVdV) indepen-
dentlyassessedeligiblestudiesforinclusion.Disagree-
ments were resolved by discussion. The following
characteristics were extracted from each selected
study: age range, prevalence of inflammatory bowel
disease in the study population (pretest probability);
percentage of patients with Crohn’s disease and per-
centage with ulcerative colitis in the group of con-
firmed cases with inflammatory bowel disease;
reference standard; faecal calprotectin assay; cut-off
value for faecal calprotectin; and data for construction
of a two by two table. Authors were contacted in cases
where information was missing to construct a two by
two table.
Assessment of methodological quality
StudyqualitywasassessedusingtheQUADAS(QUal-
ity Assessment of studies of Diagnostic Accuracy
included in Systematic reviews) checklist.
9 Each item
is scored as “yes,”“ no,” or “unclear.” We did not cal-
culate summary scores because their interpretation is
problematic and potentially misleading.
10 From the
QUADAS checklist we chose seven of the best differ-
entiating items (box).
Patients representative of those to receive the test in
practice
If patients had suspected inflammatory bowel disease
onthebasisoftheirclinicalpresentation,wescoredthe
studies as “yes.” We scored studies as “no” that
excluded patients with “other somaticbowel disorders
than inflammatory bowel disease or irritable bowel
Items chosen to score from QUADAS checklist
9
 Was the spectrum of patients representative of those who will receive the test in
practice?
 Wasthereferencestandardlikelyto correctlyclassifypatientswithinflammatorybowel
disease?
 Was the time period between reference standard and index test short enough to be
reasonably sure that the target condition did not change between the two tests?
 Did the whole sample or a random selection of the sample receive verification using a
reference standard?
 Did patients receive the same reference standard regardless of the index test result?
 Were thereference standard resultsinterpreted without knowledge of theresults of the
index test?
 Were withdrawals from the study explained?
Papers identified through searches of Medline and Embase (n=179)
Evaluated in detail (n=99)
Patients with suspected inflammatory bowel disease
(included in review)13-25 (n=13)
Diagnostic accuracy study (n=58)
Data extraction (n=33)
Excluded on basis of title and abstract (n=80)
Different patient spectrum26-45 (n=20)
No diagnostic accuracy study (n=41):
  Meta-analysis (n=1)
  Follow-up study (n=2)
  Narrative review (n=22)
  Editorial, letter to editor, or comment (n=14)      
  Correlation study (n=2)
Not about inflammatory bowel disease99 (n=1)
Not about endoscopy47 76-98 (n=24)
Fig 1 | Study selection
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controls and a group known to have inflammatory
bowel disease were also scored as “no,” because diag-
nostictestaccuracyislikelytobeoverestimatedinsuch
adesign.Ifinformationwasinsufficienttomakeajudg-
ment we scored the study as “unclear.”
Accuracy of reference standard
No reference standard in the diagnosis of inflamma-
tory bowel disease is 100% sensitive or 100% specific.
However, the Porto criteria that have been formulated
by the European Society for Paediatric Gastro-
enterology, Hepatology and Nutrition approach an
optimal diagnostic strategy for patients with suspected
inflammatory bowel disease.
3 The investigation
involves endoscopy of both the upper and the lower
gastrointestinal tract, with biopsies from each segment
of the gastrointestinal tract. To obtain a score of “yes,”
the studies had to have a reference standard that con-
sisted of at least ileocolonoscopy including histology.
Whenthe ileumwas not intubatedor nobiopsieswere
taken, we coded the study as “no.” If colonoscopy and
histology were done but information on ileal intuba-
tion was insufficient we scored the study as “unclear.”
Suitable time between reference standard and index test
Ideally, faecal sampling is done shortly before endo-
scopy, before preparation of the bowel. A delay of up
to one month was not considered problematic as it is
unlikelythatmucosalinflammationspontaneouslydis-
appearswithinthisperiod.Wethereforescoredstudies
with a delay of less than one month as “yes” and those
Table 1 |Overview of 13 included and 20 excluded diagnostic accuracy studies comparing faecal calprotectin with endoscopy
Study Patient spectrum Age group Target disease
Included studies:
Limburg 2000
18 Chronic diarrhoea Adults Inflammatory bowel disease*
Tibble 2000
25 Suspected inflammatory bowel disease Adults Inflammatory bowel disease†
Schroder 2007
23 Chronic diarrhoea Adults Inflammatory bowel disease
Schoepfer 2007
21 Suspected inflammatory bowel disease Adults Inflammatory bowel disease*
Otten 2008
19 Suspected inflammatory bowel disease Adults Inflammatory bowel disease
Schoepfer 2008
22 Suspected inflammatory bowel disease Adults Inflammatory bowel disease
Bunn 2001
14 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease
Fagerberg 2005
16 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease*
Canani 2006
15 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease
Kolho 2006
17 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease‡
Sidler 2008
24 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease
Ashorn 2009
13 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease
Perminow 2009
20 Suspected inflammatory bowel disease Children and teenagers Inflammatory bowel disease§
Excluded studies:
Summerton 2002
44 Miscellaneous gastrointestinal tract symptoms Adults Intestinal inflammation
Costa 2003
28 Out patient clinic Adults Organic disorder
Silberer 2005
40 Known inflammatory bowel disease Adults Organic disorder
Kaiser 2007
35 Known inflammatory bowel disease Adults Active disease
D’Inca 2007
29 Known inflammatory bowel disease Adults Intestinal inflammation
Shitrit 2007
39 Miscellaneous gastrointestinal tract symptoms Adults Abnormal histology
Langhorst 2008
36 Known inflammatory bowel disease Adults Active disease
Sipponen 2008
41 Known Crohn’s disease Adults Active disease
Sipponen 2008
42 Known Crohn’s disease Adults Mucosal healing
Sipponen 2008
43 Known Crohn’s disease Adults Active disease
Jones 2008
34 Known Crohn’s disease Adults Active disease
Wagner 2008
45 Known inflammatory bowel disease Adults Active disease
Damms 2008
30 Miscellaneous gastrointestinal tract symptoms Adults Intestinal inflammation
Schoepfer 2009
38 Known ulcerative colitis Adults Active disease
Jeffery 2009
33 Miscellaneous gastrointestinal tract symptoms Adults Organic disorder
Carroccio 2003
27 Chronic diarrhoea Adults and children Organic disorder
Fagerberg 2007
32 Known and suspected inflammatory bowel disease Children Active disease
Diamanti 2008
31 Known inflammatory bowel disease Children Active disease
Canani 2008
26 Known inflammatory bowel disease Children Active disease
Quail 2009
37 Known inflammatory bowel disease Children Inflammatory bowel disease¶
*2×2 table for target condition inflammatory bowel disease is constructed from data presented in original paper.
†Post hoc exclusion of patients with ulcerative colitis, as they “do not normally pose a diagnostic problem and a screening test is therefore unlikely
to be required or helpful.”
‡Over 50% of faeces samples were taken up to three months after endoscopy.
§2×2 table based on published and unpublished data.
¶Review bias (study design not according to prototype flow diagram diagnostic accuracy study).
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cient information was provided we scored the study as
“unclear.”
Sample type verified using reference standard
Partialverificationbiasoccurswhennotallofthestudy
group receives confirmation of the diagnosis by endo-
scopy.Whenitwasclearfromthestudythatallpatients
who collected faeces for measurement of calprotectin
levelhadtheirdiseasestatusverifiedbyendoscopy,we
scoredthisitemas“yes.”Studiesscored“no”ifsomeof
the patients did not undergo the reference standard
and the selection of patients to receive the reference
standard was not random.
Consistency of reference standard
Differential verification bias occurs when the perfor-
mance of the faecal calprotectin test is verified by a
different reference standard. If patients had inflamma-
tory bowel disease verified by the same type of endo-
scopy we scored this item as “yes.” If some patients
received verification by sigmoidoscopy instead of
another procedure, such as colonoscopy, we scored
this item as “no,” as there is a risk of missing right
sided colitis.
Interpretation of results
Faecal sampling for measurement of calprotectin level
was carried out before endoscopy, and analysis was
mostly done by laboratory technicians who had no
information on the endoscopy results. However, this
design precluded that faecal calprotectin results were
sometimes known to the endoscopist before endo-
scopic evaluation. This could influence the inter-
pretation of macroscopic abnormalities seen during
endoscopy. In that case we scored this item as “no.” If
insufficient information was provided we scored the
study as “unclear.”
Explanation of withdrawals
When it was clear what happened to all patients who
entered the study, we scored this item as “yes.” When
withdrawalswerenotexplained,wescoredthisitemas
“no.”
Data synthesis and analysis
Wecalculatedsensitivityandspecificityforeachstudy
and analysed these as bivariate data by methods for
diagnostic meta-analysis.
11 This approach accounts
for possible within study negative correlation between
sensitivityandspecificity.Wepresentthedataasforest
plots and receiveroperatingcharacteristic curves. For-
est plots display the diagnostic probabilities of indivi-
dual studies, the corresponding 95% confidence
intervals, and squares with area proportional to study
weight in the meta-analysis. The receiver operating
characteristiccurvesshowindividualstudydatapoints
as circles, with size proportional to study weight, the
95% confidence and 95% prediction regions around
the pooled estimate, and the hierarchical summary
curve resulting from the hierarchical summary recei-
veroperatingcharacteristicmodel.Wecarriedoutpre-
defined subgroup analyses for adults and for children.
The z test (two sided at 5% level of significance) was
used to separately compare the pooled estimates of
sensitivity and specificity of the two groups. Finally,
we calculated the average likelihood ratio of the posi-
tive and negative test result for both subgroups.
Computations were carried out with the library Diag-
Meta of the R-package (www.r-project.org/),
12 and
with STATA (version 11), in particular the metandi
commands.
RESULTS
The study includes results of electronic searches up to
14October2009.Atotalof179paperswereidentified,
of which 99 were retrieved for full text review. Of
these,66wereexcludedastheywereunrelatedtodiag-
nosticaccuracystudiesordidnotuseendoscopyasthe
reference standard. Of 33 diagnostic accuracy studies
Limburg 200018
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Fig 2 | Summary of methodological quality of included studies
on basis of review authors’ judgments on seven best
differentiating items from QUADAS checklist for each study
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scopy as the reference test, 13 focused on the desired
patient spectrum and were included in the final analy-
sis (fig 1). Table 1 lists the characteristics of the 33
studies in which endoscopy was used as the reference
standard and explains why 20 were unsuitable for
inclusion.
The final analysis included six studies in adults and
seven in children and teenagers (age range 10 months
to19.9years).Thefaecalcalprotectintestwasusedina
total of 670 patients in the adult studies and 371 in the
remainder. Inflammatory bowel disease was con-
firmed in 32% (n=215) of the adults and in 61%
(n=226) of the children and teenagers (table 2). The
methodological quality of the studies in children and
teenagers was better than that of the studies in adults
(fig 2). All studies used a prospective study design and
enrolled consecutive outpatients with suspected
inflammatory bowel disease. Selection bias in three
adult studies was caused by the post hoc exclusion of
patients.
192223Infouradultstudiesendoscopywassub-
optimalastheileumwasnotintubatedorhistologywas
not done.
18192325 In three studies in children and teen-
agerswithdrawalswerenotexplained.
172024Threestu-
dies excluded patients with gross rectal bleeding, as
this symptom would usually prompt endoscopic eva-
luation without preliminary stool testing.
151823 Partial
and differential verification was appropriately
reported and bias was prevented in all but two adult
studies.
1925 Blinding of index test results was reported
in all but three studies in children and teenagers.
172024
Diagnostic accuracy indices
Peragegroupanalyses—Figure3presentstheforestplots
ofsensitivity(truepositiverate)and1−specificity(false
positive rate) for the 13 studies. Figure 4 presents the
diagnostic values of the studies in a hierarchical sum-
maryreceiveroperatingcharacteristicgraph foradults
and for children and teenagers. For adults the sensitiv-
ity was 0.93 (0.85 to 0.97) and specificity 0.96 (0.79 to
0.99), and the corresponding values for children and
teenagers were 0.92 (0.84 to 0.96) and 0.76 (0.62 to
0.86). The difference between specificities of the two
groups was significant (P=0.048).
Post-test probability of inflammatory bowel disease—On
the basis of the pooled estimates of sensitivity and spe-
cificity, the average likelihood ratio of the positive and
negative test result was calculated for adults and for
children and teenagers. The use of faecal calprotectin
testing changed the post-test probability of inflamma-
tory bowel disease in both subgroups (fig 5). In adults
withsuspectedinflammatoryboweldiseaseandapret-
est probability of 32% an abnormal test result for cal-
protectin concentration increases the probability of
inflammatory bowel disease to 91% (95% confidence
interval 77% to 97%), whereas a normal test result for
calprotectin concentration reduces the probability to
3% (1% to 11%). In children and teenagers with
suspected inflammatory bowel disease the pretest
probability is 61%. An abnormal test result for calpro-
tectin increases the probability to 86% (78% to 92%),
whereas a normal test result for calprotectin reduces
the probability to 15% (7% to 28%).
Table 2 |Population and study characteristics of included studies
Study
No of
patients
included in
meta-
analysis
Age range
(years)
Prevalence (%)
Patients
with rectal
bleeding
included
Faecal calprotectin
assay
Reference standard
Ileal
intubation
Inflamma-
tory bowel
disease
Crohn’s
disease:
ulcerative
colitis*
Assay
type
Cut-off
value
(μg/g)
Adults
Limburg 2000
18 110 21-85 15 NK No PhiCal 100 Colonoscopy No
Tibble 2000
25 210 16-85 14 100:0 Yes Roseth 150 Colonoscopy (67%) NK
Schroder 2007
23 76 20-75 59 56:44 No PhiCal 24 Colonoscopy and histology NK
Schoepfer 2007
21 56 19-88 64 67:33 Yes PhiCal 50 Colonoscopy and histology Yes
Otten 2008
19 114 NK 20 NK Yes PhiCal 50 Colonoscopy†, histology (50%) NK
Schoepfer 2008
22 94 20-79 68 56:44 Yes PhiCal 50 Colonoscopy and histology Yes
Total 670 — 32 —— — — — —
Childrenandteenagers
Bunn 2001
14 22 2.3-15.0 59 15:69 Yes Roseth 32 Colonoscopy and histology NK
Fagerberg 2005
16 36 6.5-17.8 56 50:35 Yes PhiCal 50 Colonoscopy and histology Yes
Canani 2006
15 45 NK 60 63:37 No PhiCal 95 Colonoscopy and histology NK
Kolho 2006
17 57 0.9-18.0 54 29:52 Yes PhiCal 50 Colonoscopy and histology Yes
Sidler 2008
24 61 2.2-16.0 51 97:3 Yes PhiCal 50 Upper GIendoscopy,colonoscopy,and histology Yes
Ashorn 2009
13 55 5.8-19.9 80 34:57 Yes PhiCal 100 Upper GIendoscopy,colonoscopy,and histology NK
Perminow 2009
20 95 0.8-18.0 63 63:31 Yes PhiCal 50 Upper GIendoscopy,colonoscopy,and histology Yes
Total 371 — 61 —— — — — —
NK=not known; GI=gastrointestinal. PhiCal (Calprest) is a commercial enzyme linked immunosorbent assay (CALPRO AS, Oslo, Norway). Roseth is an in house enzyme linked immunosorbent
assay
8 (results obtained with Roseth can be compared with those obtained with Phical by multiplying former by a factor of 5.
74
*In children and teenagers remainder of inflammatory bowel disease cases was classified as indeterminate colitis.
†4% sigmoidoscopy.
RESEARCH
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In our meta-analysis we included six studies in adults
and seven in children and teenagers, which were
selected for their methodological robustness. In these
studiesdatacollectionwasdoneprospectivelyinacon-
secutiveseriesofpatientswithsuspectedinflammatory
bowel disease. All included studies used the fully
paired design where patients first undergo faecal cal-
protectin testing and then endoscopy. In the adult stu-
dies the pooledsensitivityof faecal calprotectin testing
was0.93(95%confidenceinterval0.85to0.97)andthe
pooled specificity was 0.96 (0.79 to 0.99). The corre-
sponding values in the studies in children and teen-
agers were 0.92 (0.84 to 0.96) and 0.76 (0.62 to 0.86).
The lower specificity in the studies of children and
teenagers was significantly different from that in the
adult studies. Five adult studies that included a rela-
tively large proportion of patients with irritable bowel
syndrome had significantly higher specificity.
1921-2325
This gastrointestinal syndrome, characterised by
chronic abdominal pain and altered bowel habits in
the absence of any organic cause, was hardly diag-
nosed(7%,27/371)inthestudypopulationofchildren
and teenagers. According to British Society of Gastro-
enterology guidelines, patients with irritable bowel
syndrome without alarm features (including anaemia,
weightloss,andage>50years)donotneedendoscopic
evaluation, because of a low likelihood of identifying
organicdisease.
46Thefiveadultstudiesthatincludeda
large proportion of patients with irritable bowel dis-
ease did not report the presence of alarm features.
Absence of alarm symptoms is likely to overestimate
the specificity of faecal calprotectin. In theory, the
inclusion of infants and young children (under
5 years) in four of the studies could be a reason for
lower specificity.
14172024 At this age stool samples are
usually collected from a nappy. This sampling techni-
que could increase the level of faecal calprotectin
because water is absorbed by the nappy.
47 As most
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Fig 3 | Forest plots of sensitivity and 1−specificity of faecal calprotectin test in distinguishing
inflammatory bowel disease from non-inflammatory bowel disease. Plots display diagnostic
probabilities of included studies, corresponding 95% confidence intervals, and squares with
area proportional to study weight in meta-analysis
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Fig 4 | Receiver operating characteristic graph of faecal
calprotectin test in distinguishing inflammatory bowel
disease from non-inflammatory bowel disease, with 95%
confidence region and 95% prediction regions for studies in
adults and in children and teenagers. The confidence region
consists of the most likely values of true summary sensitivity
and specificity. It indicates the precision with which the
summary points are estimated. The prediction region predicts
the true sensitivity and specificity of a future study. The size
of this region reflects the variation between studies.
Individual study estimates are represented as circles, with
size proportional to study weight
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bowel disease are teenagers, we do not think that this
mechanismplayedanimportantrole.Thechoiceofthe
faecalcalprotectincutpointcouldbeanotherreasonfor
the higher specificity in adults. However, we found no
difference between the groups in a subgroup analysis
comparing studies using a cut point of ≤50 μg/g and of
>50 μg/g. Prevalence of inflammatory bowel disease
had no effect on specificity, just as with the exclusion
of patients with rectal bleeding. Quality items also had
no significant influence on diagnostic characteristics.
Implications of key findings
We aimed to determine whether faecal calprotectin
can serve as a screening test to reduce the number of
peopleundergoinginvasiveendoscopy.Tomovefrom
theevidencegatheredinthismeta-analysistoarecom-
mendation for a screening strategy we used the com-
prehensive and transparent GRADE approach.
48
Recognising that the diagnostic accuracy of faecal cal-
protectin is a surrogate for outcomes important to
patients is central to this approach. Screening patients
by measuringfaecal calprotectin levels is of value only
if it results in improved outcomes for patients. For this
reason we infer the effect of faecal calprotectin screen-
ingonpatientoutcomefromthepooledsensitivityand
specificity. Key questions are whether the numbers of
false negatives (missed cases) and false positives (cases
withoutinflammatoryboweldiseasewhogoontohave
endoscopy) are acceptable when faecal calprotectin is
introduced as a screening test. In the “new” diagnostic
pathway patients only with suspected inflammatory
bowel disease and an abnormal faecal calprotectin
result will be sent urgently for endoscopy (fig 6).
Table 3showstheimplicationsofthetestingscenarios.
In a hypothetical population of 100 adults with sus-
pected inflammatory bowel disease (and an overall
mean prevalence of 32%) three patients without the
disease would go on to have endoscopy and two
patients with the disease would be missed. Faecal cal-
protectinscreeningwouldreducethenumberofadults
requiring endoscopy by 67%. In a hypothetical popu-
lation of 100 children and teenagers with suspected
inflammatorybowel disease(and an overallmean pre-
valence of 61%) nine without the disease would go on
to have endoscopy, five with the disease would be
missed,andfaecalcalprotectinscreeningwouldreduce
the number requiring endoscopy by 35%.
The clinical consequences of missing patients with
inflammatory bowel disease should be balanced
against patients without the disease who go on to
have endoscopy. A false negative faecal calprotectin
test result would lead to a failure to introduce effective
treatment in a timely manner, with the resultant con-
tinuation of symptoms. A false positive test result
means that people endure an invasive procedure. A
considerable proportion of the patients with a false
positive test result will, however, prove to have a
gastrointestinalconditiondifferentfrominflammatory
bowel disease (table 4) for which endoscopy is inevi-
table.Complicationsofendoscopy,relatedtotheinva-
siveness of the procedure itself (colonic perforation or
tear) or to anaesthesia, are also important considera-
tions,althoughtheyare rare.Severalretrospectivestu-
dies havereportedthe incidence ofa smallperforation
after colonoscopy to be in the range 0.032% (1 in 3115
patients) to 0.9% (1 in 111).
49-51
We consider faecal calprotectin a useful screening
tool for identifying those patients who are most likely
to need endoscopy for inflammatory bowel disease.
Adding calprotectin testing to the diagnostic pathway,
however,also resulted in delayeddiagnosisin 6% (2 in
32 patients) of the adults and 8% (5 in 61) of the chil-
drenandteenagers.Healthprofessionalsmaybeinter-
ested in finding ways to ease the pressure on
overstretched endoscopy centres with long waiting
lists. Increased faecal calprotectin levels may indicate
a need for urgent endoscopy, whereas normal calpro-
tectin levels are less likely to be associated with intest-
inal inflammation and further investigations can be
tailored appropriately. The only exception to this
rule is the presence of persistent rectal bleeding,
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Fig 5 | Fagan’s nomogram for faecal calprotectin showing post-test probability of inflammatory
bowel disease after abnormal test result (upper line) and normal test result (lower line) in
adults and in children and teenagers
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Urgent endoscopy
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Plan other investigations Start treatment for
inflammatory bowel disease
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Fig 6 | Recommended position of faecal calprotectin in
diagnostic pathway
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able to that for increased levels of faecal calprotectin.
Comparison with other reviews
A total of 22 narrative reviews have been published in
recentyearsontheuseoftestingforfaecalcalprotectin
levels in the diagnosis of intestinal inflammation or
flare-up of inflammatory bowel disease (fig 1), but all
were based on non-systematic methods.
52-73 One sys-
tematic approach summarised the findings of all avail-
able studies to 2006.
74 The reviewers found higher
sensitivity and specificity for the diagnosis of inflam-
matory bowel disease than we did. The meta-analysis
of that review, however, had several methodological
limitations. Sensitivity and specificity were pooled
separately contrary to general recommendations and
the reviewers included studies that featured a control
group with healthy people, which leads to overestima-
tion of diagnostic accuracy.
75
Methodological limitations of the review
We reviewed the diagnostic accuracy of faecal calpro-
tectin levels according to the most recent insights and
methodsfordiagnostic meta-analyses.Theresultscan,
however, be biased by the use of the reference stan-
dard. Although we included studies that used endo-
scopy with histopathological verification of segmental
biopsies, we included two studies in adults that did not
sample intestinal mucosa.
1825 It is possible that some
patientsweremisclassifiedbecauseofanormalmacro-
scopic appearance of the mucosa, whereas micro-
scopic evaluation would have shown abnormalities
typical of the disease. However, even ileocolonoscopy
combined with histology is not an ideal method. The
gastrointestinal tract can only be partly visualised with
conventional endoscopy. The reported pooled sensi-
tivity of faecal calprotectin could thus be slightly over-
estimated.
We tried to reduce spectrum bias by including only
studies with a patient population representative of
patients seen in usual clinical care. None of the studies
used a well defined set of clinical findings (clinical pre-
dictionrules)orflowchartthatidentifiespatientswitha
high probability of inflammatory bowel disease.
Becauseofthelimitednumberofstudiesincludedin
this meta-analysis we were not able to assess the diag-
nosticaccuracyoffaecalcalprotectinatdifferentcut-off
values. Most of the included studies used the cut-off as
advised by the manufacturer (50 μg/g).
161719-2224
Others based the cut-off on their own receiver operat-
ing characteristic curves,
2325 or on the 95th centile of
the normal range in children and teenagers.
1415
We could not control for time between calprotectin
testing and the reference standard. Ideally faecal sam-
pling was done shortly before endoscopy, but a delay
of up to one month was not considered problematic.
One study in children and teenagers did not meet this
Table 3 |Consequences of pooled sensitivity and specificity of faecal calprotectin for patient outcome
Test result
No per 100 patients (prevalence of IBD)
Presumed influence on patient outcome Importance*
Adults
(32%)
Children and teenagers
(61%)
True positive 30 56 Benefit from shorter delay and early treatment 8
True negative 65 30 Benefit from reassurance and avoidance of unnecessary
invasive procedure
8
False positive 3 9 Detriment from exposure to invasive procedure; may benefit
from endoscopy for correct diagnosis
7
False negative 2 5 Detriment from delayed diagnosis 9
Complications —— Not reliably reported 5
Cost —— No data available 3
IBD=inflammatory bowel disease.
*GRADE recommends classifying patient important outcomes on a 9 point scale: 7-9: critical for decision making; 4-6: important but not critical for
decision making; and 1-3: of lower importance to patients.
109
Table 4 |Causes of abnormal results for faecal calprotectin
other than inflammatory bowel disease
Condition References
Infections:
Giardia lamblia 100
Bacterial dysentery 15;30;35;76;78;87;93;100
Viral gastroenteritis 35;101
Helicobacter pylori gastritis 24
Malignancies:
Colorectal cancer 8;25;28-30;44;82;102
Gastric carcinoma 44
Intestinal lymphoma 28
Drugs:
Non-steroidalanti-inflammatorydrugs 76;82;100;103
Proton pump inhibitors 104
Food allergy (untreated) 14;18;27;76
Other gastrointestinal diseases:
Gastro-oesophageal reflux disease 24;78
Cystic fibrosis 87;105
Coeliac disease (untreated) 27;76;78;82;100
Diverticular disease 18;25;27;29;44;100
Protein losing enteropathy 76
Colorectal adenoma 18;25;29;30
Juvenile polyp 16;17;87
Autoimmune enteropathy 99
Microscopic colitis 18;25;106
Liver cirrhosis 107
Young age (<5 years) 47;91;108
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being collected up to three months after endoscopy.
17
We suspected a possible overlap of two patient
cohorts described by one research group,
2122 and
thereforecontactedtheauthorsbyemail.Theyreplied
that there was no overlap of the two patient cohorts as
thesewere different studyprotocols. Eachof themhad
been approved by the local institutional review board.
Finally,werestrictedoursearchtostudiespublished
in English only. This could have been a potential
source of bias.
Applicability of findings to primary care practice
The value of faecal calprotectin for screening of
patients with suspected inflammatory bowel disease
was evaluated in tertiary care facilities, with the excep-
tion of one secondary level hospital.
19 The Fagan plot
(fig 5) presents the predictive values corresponding to
the prevalences in this tertiary level context. The plot
readily facilitates reading off predictive values corre-
sponding to a lower prevalence in primary care. For
example, on decreasing the prevalence (pretest prob-
ability) in adults from 32% to 5%, the positive predic-
tive value of the faecal calprotectin test decreases to
about 55% whereas the negative predictive value
increases above 99.8%. (This assumes that likelihood
ratios remain constant across the spectrum of care.)
The emphasis in tertiary care is usually on “ruling
in”: increasing the probability of inflammatory bowel
disease to carry out more expensive, time consuming,
and invasive procedures; establish a firm diagnosis;
and start appropriate treatment. At tertiary care level
a diagnostic test with a high positive likelihood ratio is
preferred. In primary care, where the prevalence of
inflammatory bowel disease is low, the emphasis is
on “ruling out”: lowering the probability of the target
diseaseto providereassurance, or toadopta “watchful
waiting” strategy. In these instances tests with a low
negative likelihood ratio are preferred. In view of the
abovewearereservedabouttheutilityoffaecalcalpro-
tectin in primary care practice, and we certainly dis-
courage its use to screen asymptomatic patients.
Conclusions
Measuring faecal calprotectin levels is a useful screen-
ing tool for identifying patients who are most likely to
need endoscopy for suspected inflammatory bowel
disease. The discriminative power to safely exclude
the disease (specificity) is significantly better in studies
ofadults thaninstudiesofchildrenandteenagers.At a
tertiary care level faecal calprotectin levels can contri-
buteimportantinformationandguidepatientmanage-
ment. The pooled sensitivity and specificity, however,
should be interpreted with caution. Despite a strict
selection of studies based on proper patient recruit-
ment and study design, heterogeneity was consider-
able.
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